PMID- 32339244
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20210520
IS  - 1943-7730 (Electronic)
IS  - 0007-5027 (Linking)
VI  - 51
IP  - 5
DP  - 2020 Sep 1
TI  - Intravenous Immunoglobulin-Associated Hemolytic Anemia.
PG  - e47-e50
LID - 10.1093/labmed/lmaa019 [doi]
AB  - Intravenous immunoglobulin (IVIG) is an important therapeutic tool for the 
      treatment of a variety of conditions, including immune thrombocytopenic purpura 
      (ITP). Although IVIG has many approved indications and is typically well 
      tolerated, a number of adverse effects have been reported. Hemolysis is a 
      documented but under-recognized adverse effect associated with large individual 
      or cumulative doses of IVIG. Hemolytic complications are typically mild and 
      detected incidentally when screening tests, such as a complete blood count (CBC) 
      showing decreased hemoglobin or a complete metabolic panel (CMP) resulting in 
      elevated bilirubin, are performed for another reason. Herein, we report a case of 
      significant hemolytic anemia in a 59 year old Caucasian woman, who required 
      packed red blood cell transfusion after administration of IVIG for the treatment 
      of ITP. Increased awareness of the potential for clinically significant hemolysis 
      after the use of moderate cumulative doses of IVIG is needed, particularly in 
      patients with risk factors for hemolysis.
CI  - (c) American Society for Clinical Pathology 2020. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Jacobs, Jeremy
AU  - Jacobs J
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, Tennessee.
FAU - Kneib, Jessica
AU  - Kneib J
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, Tennessee.
FAU - Gabbard, Amy
AU  - Gabbard A
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, Tennessee.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Lab Med
JT  - Laboratory medicine
JID - 0250641
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Anemia, Hemolytic/*chemically induced
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*adverse effects
MH  - Middle Aged
MH  - Purpura, Thrombocytopenic, Idiopathic/*drug therapy
EDAT- 2020/04/28 06:00
MHDA- 2021/05/21 06:00
CRDT- 2020/04/28 06:00
PHST- 2020/04/28 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
PHST- 2020/04/28 06:00 [entrez]
AID - 5825742 [pii]
AID - 10.1093/labmed/lmaa019 [doi]
PST - ppublish
SO  - Lab Med. 2020 Sep 1;51(5):e47-e50. doi: 10.1093/labmed/lmaa019.